Alpha 2.0
Login Register
» Authors » Alexander Gutin

Alexander Gutin

Explore the profile of Alexander Gutin including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 54
Citations 5613
Followers 0
Related Specialties
Oncology
Genetics
General Medicine
Top 10 Co-Authors
Jerry S Lanchbury
Elisha Hughes
Victor Abkevich
Susanne Wagner
Kirsten M Timms
Julia Reid
Darl D Flake 2nd
Steven Stone
Diana Iliev
Zaina Sangale
Published In
JCO Precis Oncol
Breast Cancer Res Treat
Clin Cancer Res
Hum Mol Genet
Am J Hum Genet
Affiliations
Soon will be listed here.
Recent Articles
1.
Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing
Lenz L, Clegg W, Iliev D, Kasten C, Korman H, Morgan T, et al.
Prostate Cancer Prostatic Dis . 2024 Sep; PMID: 39237680
Background: Genomic testing can add risk stratification information to clinicopathological features in prostate cancer, aiding in shared medical decision-making between the clinician and patient regarding whether active surveillance (AS) or...
2.
Validation of a clinical breast cancer risk assessment tool combining a polygenic score for all ancestries with traditional risk factors
Mabey B, Hughes E, Kucera M, Simmons T, Hullinger B, Pederson H, et al.
Genet Med . 2024 Jun; 26(7):101128. PMID: 38829299
Purpose: We previously described a combined risk score (CRS) that integrates a multiple-ancestry polygenic risk score (MA-PRS) with the Tyrer-Cuzick (TC) model to assess breast cancer (BC) risk. Here, we...
3.
Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer
Tward J, Lenz L, Gutin A, Clegg W, Kasten C, Finch R, et al.
JCO Precis Oncol . 2024 May; 8:e2300722. PMID: 38748970
Purpose: Guidelines recommend adding androgen-deprivation therapy (ADT) to radiation therapy (RT) in certain patients with localized prostate cancer. Individualized genomic testing may improve the prognostic accuracy of risk assessments. Herein,...
4.
External validation of a multi-biomarker-based score for predicting risk of cardiovascular disease in patients with rheumatoid arthritis
Sasso E, Mabey B, Flake 2nd D, Hitraya E, Chin C, Ben-Shachar R, et al.
PLoS One . 2024 May; 19(5):e0296459. PMID: 38709770
Background: A multi-biomarker disease activity (MBDA)-based cardiovascular disease (CVD) risk score was developed and internally validated in a Medicare cohort to predict 3-year risk for myocardial infarction (MI), stroke or...
5.
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes
Lenz L, Neff C, Solimeno C, Cogan E, Abramson V, Boughey J, et al.
Breast Cancer Res Treat . 2023 Aug; 202(1):191-201. PMID: 37589839
Purpose: A 3-biomarker homologous recombination deficiency (HRD) score is a key component of a currently FDA-approved companion diagnostic assay to identify HRD in patients with ovarian cancer using a threshold...
6.
The association between age at breast cancer diagnosis and prevalence of pathogenic variants
Daly M, Rosenthal E, Cummings S, Bernhisel R, Kidd J, Hughes E, et al.
Breast Cancer Res Treat . 2023 Apr; 199(3):617-626. PMID: 37084156
Purpose: Young age at breast cancer (BC) diagnosis and family history of BC are strongly associated with high prevalence of pathogenic variants (PVs) in BRCA1 and BRCA2 genes. There is...
7.
Development and Validation of a Breast Cancer Polygenic Risk Score on the Basis of Genetic Ancestry Composition
Hughes E, Wagner S, Pruss D, Bernhisel R, Probst B, Abkevich V, et al.
JCO Precis Oncol . 2022 Nov; 6:e2200084. PMID: 36331239
Purpose: Polygenic risk scores (PRSs) for breast cancer (BC) risk stratification have been developed primarily in women of European ancestry. Their application to women of non-European ancestry has lagged because...
8.
Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
Constantinidou A, Marcou Y, Toss M, Simmons T, Bernhisel R, Hughes E, et al.
Clin Cancer Res . 2022 Aug; 28(20):4435-4443. PMID: 36043530
Purpose: The EndoPredict prognostic assay is validated to predict distant recurrence and response to chemotherapy primarily in post-menopausal women with estrogen receptor-positive (ER+), HER2- breast cancer. This study evaluated the...
9.
Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women
Kurian A, Hughes E, Handorf E, Gutin A, Allen B, Hartman A, et al.
JCO Precis Oncol . 2022 Feb; 1:1-12. PMID: 35172496
Purpose: Multiple-gene, next-generation sequencing panels are increasingly used to assess hereditary cancer risks of patients with diverse personal and family cancer histories. The magnitude of breast and ovarian cancer risk...
10.
Comprehensive Breast Cancer Risk Assessment for and Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model
Gallagher S, Hughes E, Kurian A, Domchek S, Garber J, Probst B, et al.
JCO Precis Oncol . 2021 Jul; 5. PMID: 34322652
Purpose: Breast cancer risks for and pathogenic variant (PV) carriers are modified by an 86-single nucleotide polymorphism polygenic risk score (PRS) and individual clinical factors. Here, we describe comprehensive risk...